{"entity":{"type":"insider","cik":"0001602396","url":"/insider/0001602396","json_url":"/insider/0001602396.json","name":"Hadas Nicole R.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":32,"n_filings":25,"first":"2014-03-27","last":"2024-05-14","span_basis":"filed_date"},"name_variants":[{"name":"Hadas Nicole R.","source":"filing","n_filings":25,"first_seen":"2014-03-27","last_seen":"2024-05-14"}],"transactions":[{"id":2288825,"accession":"0001562180-24-004026","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-24-004026","line_url":"/filing/0001562180-24-004026#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12016.0,"shares_display":"12,016","price_per_share":1.26,"price_display":"1.26","price_state":"stated","total_value":15140.16,"total_display":"15,140.16","total_whole":"15,140","shares_owned_after":651243.0,"shares_owned_after_display":"651,243","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-13","filed_date":"2024-05-14","scope":"insider"},{"id":2728842,"accession":"0001562180-24-002022","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-24-002022","line_url":"/filing/0001562180-24-002022#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5974.0,"shares_display":"5,974","price_per_share":1.58,"price_display":"1.58","price_state":"stated","total_value":9438.92,"total_display":"9,438.92","total_whole":"9,439","shares_owned_after":663259.0,"shares_owned_after_display":"663,259","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-29","filed_date":"2024-03-01","scope":"insider"},{"id":2789730,"accession":"0001562180-24-001995","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-24-001995","line_url":"/filing/0001562180-24-001995#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7411.0,"shares_display":"7,411","price_per_share":1.52,"price_display":"1.52","price_state":"stated","total_value":11264.72,"total_display":"11,264.72","total_whole":"11,265","shares_owned_after":669233.0,"shares_owned_after_display":"669,233","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-29","scope":"insider"},{"id":8634225,"accession":"0001562180-23-004504","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-23-004504","line_url":"/filing/0001562180-23-004504#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":63186.0,"shares_display":"63,186","price_per_share":1.2229,"price_display":"1.22","price_state":"stated","total_value":77270.1594,"total_display":"77,270.16","total_whole":"77,270","shares_owned_after":524344.0,"shares_owned_after_display":"524,344","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-05-25","filed_date":"2023-05-25","scope":"insider"},{"id":8006995,"accession":"0001562180-23-002200","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-23-002200","line_url":"/filing/0001562180-23-002200","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13034.0,"shares_display":"13,034","price_per_share":0.8775,"price_display":"0.88","price_state":"stated","total_value":11437.335,"total_display":"11,437.34","total_whole":"11,437","shares_owned_after":288618.0,"shares_owned_after_display":"288,618","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-01","filed_date":"2023-03-03","scope":"insider","n_lines":3},{"id":8688044,"accession":"0001562180-23-002037","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-23-002037","line_url":"/filing/0001562180-23-002037#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6677.0,"shares_display":"6,677","price_per_share":0.8132,"price_display":"0.81","price_state":"stated","total_value":5429.7364,"total_display":"5,429.74","total_whole":"5,430","shares_owned_after":300564.0,"shares_owned_after_display":"300,564","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-03-01","scope":"insider"},{"id":6347866,"accession":"0001562180-22-002161","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001562180-22-002161","line_url":"/filing/0001562180-22-002161","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14507.0,"shares_display":"14,507","price_per_share":2.1707,"price_display":"2.17","price_state":"stated","total_value":31490.3449,"total_display":"31,490.34","total_whole":"31,490","shares_owned_after":308875.0,"shares_owned_after_display":"308,875","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-03-01","filed_date":"2022-03-02","scope":"insider","n_lines":3},{"id":6347857,"accession":"0001562180-22-002161","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-22-002161","line_url":"/filing/0001562180-22-002161#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6555.0,"shares_display":"6,555","price_per_share":2.1548,"price_display":"2.15","price_state":"stated","total_value":14124.714,"total_display":"14,124.71","total_whole":"14,125","shares_owned_after":265748.0,"shares_owned_after_display":"265,748","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-02-28","filed_date":"2022-03-02","scope":"insider"},{"id":4940631,"accession":"0001562180-21-002542","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-21-002542","line_url":"/filing/0001562180-21-002542#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1060.0,"shares_display":"1,060","price_per_share":3.4,"price_display":"3.40","price_state":"stated","total_value":3604.0,"total_display":"3,604.00","total_whole":"3,604","shares_owned_after":272303.0,"shares_owned_after_display":"272,303","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-04-01","filed_date":"2021-04-01","scope":"insider"},{"id":4234430,"accession":"0001562180-21-001785","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001562180-21-001785","line_url":"/filing/0001562180-21-001785","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":14285.0,"shares_display":"14,285","price_per_share":3.3961,"price_display":"3.40","price_state":"stated","total_value":48513.2885,"total_display":"48,513.29","total_whole":"48,513","shares_owned_after":263171.0,"shares_owned_after_display":"263,171","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-03-01","filed_date":"2021-03-02","scope":"insider","n_lines":2},{"id":2580310,"accession":"0001562180-20-001936","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-20-001936","line_url":"/filing/0001562180-20-001936#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, Chief Legal Officer)","role_mark":"O","role_mark_label":"Officer (SVP, Chief Legal Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, Chief Legal Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7050.0,"shares_display":"7,050","price_per_share":8.7,"price_display":"8.70","price_state":"stated","total_value":61335.0,"total_display":"61,335.00","total_whole":"61,335","shares_owned_after":212756.0,"shares_owned_after_display":"212,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2020-02-28","filed_date":"2020-03-02","scope":"insider"},{"id":4419455,"accession":"0001562180-17-003206","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001562180-17-003206","line_url":"/filing/0001562180-17-003206","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7803.0,"shares_display":"7,803","price_per_share":19.888301935153144,"price_display":"19.89","price_state":"stated","total_value":155188.42,"total_display":"155,188.42","total_whole":"155,188","shares_owned_after":101804.0,"shares_owned_after_display":"101,804","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-02","filed_date":"2017-10-04","scope":"insider","n_lines":2},{"id":5081045,"accession":"0001562180-17-002434","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-002434","line_url":"/filing/0001562180-17-002434#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1554.0,"shares_display":"1,554","price_per_share":14.2577,"price_display":"14.26","price_state":"stated","total_value":22156.4658,"total_display":"22,156.47","total_whole":"22,156","shares_owned_after":109607.0,"shares_owned_after_display":"109,607","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-07-03","filed_date":"2017-07-06","scope":"insider"},{"id":4820713,"accession":"0001562180-17-001429","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-001429","line_url":"/filing/0001562180-17-001429#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1556.0,"shares_display":"1,556","price_per_share":9.1775,"price_display":"9.18","price_state":"stated","total_value":14280.19,"total_display":"14,280.19","total_whole":"14,280","shares_owned_after":109856.0,"shares_owned_after_display":"109,856","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-04-03","filed_date":"2017-04-04","scope":"insider"},{"id":4755250,"accession":"0001562180-17-000080","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-17-000080","line_url":"/filing/0001562180-17-000080#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1810.0,"shares_display":"1,810","price_per_share":10.4906,"price_display":"10.49","price_state":"stated","total_value":18987.986,"total_display":"18,987.99","total_whole":"18,988","shares_owned_after":82912.0,"shares_owned_after_display":"82,912","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-01","filed_date":"2017-01-03","scope":"insider"},{"id":2779204,"accession":"0001562180-16-003206","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-16-003206","line_url":"/filing/0001562180-16-003206#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1556.0,"shares_display":"1,556","price_per_share":8.9548,"price_display":"8.95","price_state":"stated","total_value":13933.6688,"total_display":"13,933.67","total_whole":"13,934","shares_owned_after":83915.0,"shares_owned_after_display":"83,915","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-01","filed_date":"2016-10-04","scope":"insider"},{"id":2462368,"accession":"0001562180-16-002777","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001562180-16-002777","line_url":"/filing/0001562180-16-002777#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1557.0,"shares_display":"1,557","price_per_share":7.4665,"price_display":"7.47","price_state":"stated","total_value":11625.3405,"total_display":"11,625.34","total_whole":"11,625","shares_owned_after":85471.0,"shares_owned_after_display":"85,471","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-07-05","filed_date":"2016-07-06","scope":"insider"},{"id":2664090,"accession":"0001209191-16-112923","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-112923","line_url":"/filing/0001209191-16-112923#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1556.0,"shares_display":"1,556","price_per_share":9.41,"price_display":"9.41","price_state":"stated","total_value":14641.96,"total_display":"14,641.96","total_whole":"14,642","shares_owned_after":85528.0,"shares_owned_after_display":"85,528","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-04-04","filed_date":"2016-04-05","scope":"insider"},{"id":2916057,"accession":"0001209191-16-089766","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-089766","line_url":"/filing/0001209191-16-089766#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1811.0,"shares_display":"1,811","price_per_share":12.28,"price_display":"12.28","price_state":"stated","total_value":22239.08,"total_display":"22,239.08","total_whole":"22,239","shares_owned_after":64584.0,"shares_owned_after_display":"64,584","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-01-04","filed_date":"2016-01-06","scope":"insider"},{"id":8649133,"accession":"0001209191-15-073788","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-073788","line_url":"/filing/0001209191-15-073788#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1484.0,"shares_display":"1,484","price_per_share":8.6657,"price_display":"8.67","price_state":"stated","total_value":12859.8988,"total_display":"12,859.90","total_whole":"12,860","shares_owned_after":65260.0,"shares_owned_after_display":"65,260","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-10-02","filed_date":"2015-10-05","scope":"insider"},{"id":8827263,"accession":"0001209191-15-059449","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-059449","line_url":"/filing/0001209191-15-059449#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1484.0,"shares_display":"1,484","price_per_share":9.5421,"price_display":"9.54","price_state":"stated","total_value":14160.4764,"total_display":"14,160.48","total_whole":"14,160","shares_owned_after":66744.0,"shares_owned_after_display":"66,744","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-07-02","filed_date":"2015-07-06","scope":"insider"},{"id":9269682,"accession":"0001209191-15-058358","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-058358","line_url":"/filing/0001209191-15-058358#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1483.0,"shares_display":"1,483","price_per_share":9.0881,"price_display":"9.09","price_state":"stated","total_value":13477.6523,"total_display":"13,477.65","total_whole":"13,478","shares_owned_after":67015.0,"shares_owned_after_display":"67,015","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-02","filed_date":"2015-07-02","scope":"insider"},{"id":8746307,"accession":"0001209191-15-032675","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-032675","line_url":"/filing/0001209191-15-032675#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1483.0,"shares_display":"1,483","price_per_share":9.0881,"price_display":"9.09","price_state":"stated","total_value":13477.6523,"total_display":"13,477.65","total_whole":"13,478","shares_owned_after":76093.0,"shares_owned_after_display":"76,093","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-04-02","filed_date":"2015-04-06","scope":"insider"},{"id":9269681,"accession":"0001209191-15-058357","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-15-058357","line_url":"/filing/0001209191-15-058357#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (SVP, General Counsel, Sec)","role_mark":"O","role_mark_label":"Officer (SVP, General Counsel, Sec)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, General Counsel, Sec.","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1715.0,"shares_display":"1,715","price_per_share":11.4607,"price_display":"11.46","price_state":"stated","total_value":19655.1005,"total_display":"19,655.10","total_whole":"19,655","shares_owned_after":68498.0,"shares_owned_after_display":"68,498","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-02","filed_date":"2015-07-02","scope":"insider"},{"id":8879078,"accession":"0001209191-15-001003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-15-001003","line_url":"/filing/0001209191-15-001003#line-2","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer (VP General Counsel & Secretary)","role_mark":"O","role_mark_label":"Officer (VP General Counsel & Secretary)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP General Counsel & Secretary","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1715.0,"shares_display":"1,715","price_per_share":11.4607,"price_display":"11.46","price_state":"stated","total_value":19655.1005,"total_display":"19,655.10","total_whole":"19,655","shares_owned_after":73037.0,"shares_owned_after_display":"73,037","ownership_form":"D","is_10b5_1":null,"transaction_date":"2015-01-02","filed_date":"2015-01-05","scope":"insider"},{"id":6294074,"accession":"0001209191-14-023438","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-023438","line_url":"/filing/0001209191-14-023438#line-1","is_derivative":false,"issuer_cik":"0001517022","issuer_name":"Akebia Therapeutics, Inc.","issuer_ticker":"AKBA","issuer_name_source":null,"issuer_url":"/issuer/0001517022","owner_cik":"0001602396","owner_name":"Hadas Nicole R.","owner_display_name":"Hadas Nicole R.","owner_url":"/insider/0001602396","role":"Officer","role_mark":"O","role_mark_label":"Officer","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"See Remarks","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3500.0,"shares_display":"3,500","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":59500.0,"total_display":"59,500.00","total_whole":"59,500","shares_owned_after":76123.0,"shares_owned_after_display":"76,123","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-03-25","filed_date":"2014-03-27","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":32,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":31,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":32},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001517022","name":"Akebia Therapeutics, Inc.","url":"/issuer/0001517022","role":"Officer (SVP, Chief Legal Officer)","n_filings":25,"first_seen":"2014-03-27","last_seen":"2024-05-14"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001602396","retrieved_at":"2026-08-24T01:08:25+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}